Company / Accounts Receivable
BeOne Medicines Ltd. Accounts Receivable History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$865.1M
FY2025
5-year range
$173.2M / $865.1M
FY2021-FY2025
Trend
+27.9%
vs FY2024
Sector context
#19 of 115
Health Care
What the data says
BeOne Medicines Ltd.'s accounts receivable of $865M is higher than 83% of companies in the Health Care sector (FY2025). Accounts Receivable has increased for 3 consecutive years, from $173M in FY2022 to $865M in FY2025.
Based on SEC 10-K filings.
$865M in FY2025 with a 5-year CAGR of +70.3%. Top quartile in the Health Care sector.
Improved from $358M to $865M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +70.9%
- 5-Year CAGR
- +70.3%
- 10-Year CAGR
- -
Sector benchmark
-22.6% below sector average
Key checks
Key Insights
- BeOne Medicines Ltd.'s accounts receivable has grown for 3 consecutive years.
- 5-year CAGR of +70.3%, indicating consistent growth.
- In FY2025, accounts receivable increased 27.9% year-over-year.
- Ranks #19 out of 115 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.82 (distress zone, below 1.8 threshold)
- Negative profit margin: -16.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $865.1M | +27.9% |
| FY2024 | $676.3M | +88.9% |
| FY2023 | $358.0M | +106.8% |
| FY2022 | $173.2M | -64.2% |
| FY2021 | $483.1M | +699.8% |
| FY2020 | $60.4M | -14.8% |
| FY2019 | $70.9M | +72.6% |
| FY2018 | $41.1M | +39.5% |
| FY2017 | $29.4M | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026